

References

1. Elkefi, S., & Asan, O. (2023). The impact of patient-centered care on cancer patients' QOC, self-efficacy, and trust towards doctors: analysis of a national survey. *Journal of Patient Experience*, 10, 23743735231151533.
2. Cella, D., Chen, C. I., Quek, R. G., Uribarren, A., Reaney, M., Mastey, V., Collyar, D., & Chassany, O. (2022). Patient-reported outcomes labeling for oncology drugs: multidisciplinary perspectives on current status and future directions. *Frontiers in Pharmacology*, 13, 1031992.
3. Gnanasakthy, A., Barrett, A., Evans, E., D'Alessio, D., & Romano, C. D. (2019). A review of patient-reported outcomes labeling for oncology drugs approved by the FDA and the EMA (2012-2016). *Value in Health*, 22(2), 203-209.
4. Final FDA guidance, 2024. Core Patient-Reported Outcomes in Cancer Clinical Trials. [Core Patient-Reported Outcomes in Cancer Clinical Trials | FDA](#)
5. Final FDA guidance, 2024. Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases. [Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases | FDA](#)
6. Byrom, B., Everhart, A., Cordero, P., Garratt, C., & Meyer, T. (2025). Leveraging Patient-Reported Outcome Measures for Optimal Dose Selection in Early Phase Cancer Trials. *JMIR cancer*, 11, e64611.
7. Basch, E., Schrag, D., et al. (2025). Symptom monitoring with electronic patient-reported outcomes during cancer treatment: final results of the PRO-TTECT cluster-randomized trial. *Nature medicine*, 1-8.